BCL7C

Across TCGA pan-cancer cohorts, BCL7C mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of BCL7C’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where BCL7C mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BCL7C is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

PDAC, LSCC, and COAD are the cancer types where BCL7C tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCL7C mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	All	III,IV	−0.398	<.001	8	view →
LSCC	Male	II,III,IV	+0.203	<.001	8	view →
COAD	All	All	+0.132	.014	4	view →
HNSC	All	III,IV	−0.099	.039	4	view →
LUAD	All	All	+0.080	.002	3	view →
OV	All	All	+0.362	.021	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

BCL7C–PDAC

Open the PDAC breakdown →